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Summary
Objective: Epilepsy is a progressive neurological disease characterized by recur-
rent seizures and behavioral comorbidities. We investigated the antiseizure effect
of cannabidiol (CBD) in a battery of acute seizure models. Additionally, we
defined the disease‐modifying potential of chronic oral administration of CBD on
associated comorbidities in the reduced intensity status epilepticus–spontaneous
recurrent seizures (RISE‐SRS) model of temporal lobe epilepsy (TLE).
Methods: We evaluated the acute antiseizure effect of CBD in the maximal elec-
troshock seizure, 6‐Hz psychomotor seizure, and pentylenetetrazol acute seizure tests,
as well as the corneal kindling model of chronic seizures in mice following intraperi-
toneal administration. Median effective or behavioral toxic dose was determined in
both mice and rats. Next, we tested an intravenous preparation of CBD (10 mg/kg sin-
gle dose) in a rat model of pilocarpine‐induced status epilepticus. We defined the
effect of chronic CBD administration (200 mg/kg orally) on spontaneous seizures,
motor control, gait, and memory function in the rat RISE‐SRS model of TLE.
Results: CBD was effective in a battery of acute seizure models in both mice and
rats following intraperitoneal administration. In the pilocarpine‐induced status
epilepticus rat model, CBD attenuated maximum seizure severity following intra-
venous administration, further demonstrating CBD’s acute antiseizure efficacy in
this rat model. We established that oral CBD attenuated the time‐dependent
increase in seizure burden and improved TLE‐associated motor comorbidities of
epileptic rats in the RISE‐SRS model without affecting gait. Chronic administra-
tion of CBD after the onset of SRS ameliorated reference memory and working
memory errors of epileptic animals in a spatial learning and memory task.
Significance: The present study illustrates that CBD is a well‐tolerated and effec-
tive antiseizure agent and illustrates a potential disease‐modifying effect of CBD
on reducing both seizure burden and associated comorbidities well after the onset
of symptomatic seizures in a model of TLE.
Williams and McNeish contributed equally.
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1 | INTRODUCTION
Epilepsy is a progressive, chronic neurological disorder char-
acterized by recurrent seizures.1 Approximately 65 million
people worldwide live with epilepsy, of whom ~30% are con-
sidered pharmacoresistant to the currently available anti-
seizure drugs (ASDs).2 Seizures, although the primary
symptom, are not the only aspect of epilepsy that affects a
patient’s quality of life. Several comorbidities (eg, depression,
anxiety, motor disorder, cognitive deficits, social dysfunction)
also contribute to a reduced quality of life in addition to the
poor prognosis associated with the disease.3 Furthermore, cur-
rently available ASDs are also known to produce a variety of
cognitive, psychiatric, and motor adverse effects4,5; thus, ther-
apies that do not carry the potential to increase the adverse
effects liability are in significant clinical demand.
Cannabis has been used since prehistoric times to treat
several diseases, including epilepsy.6 However, the thera-
peutic benefits of whole cannabis are overshadowed by its
psychoactive effects,7 which have limited its clinical use.
More than 100 phytocannabinoids have been isolated, of
which Δ9‐tetrahydrocannabinol, cannabidiol (CBD), and
cannabidivarin are considered most relevant in the treat-
ment of epilepsy; however, Δ9‐tetrahydrocannabinol has
poor clinical potential due to its psychoactive and potential
proconvulsive properties, which may limit chronic use.1,6
CBD has been shown to have antiseizure activity in several
animal models.6,8–10 Given its anticonvulsant efficacy in
phase 3 clinical trials, the US Food and Drug Administra-
tion (FDA) in 2018 approved CBD (Epidiolex; GW
Research) as a drug for the treatment of seizures associated
with Dravet syndrome or Lennox‐Gastaut syndrome in
patients 2 years of age and older.11–13
Here, we initially tested CBD in a battery of well‐estab-
lished preclinical seizure and epilepsy models following
intraperitoneal administration to define CBD’s pharmaco-
logical profile and differentiate it from other ASD standards
of care. Second, we investigated the efficacy of intravenous
(IV) pretreatment with CBD in the rat pilocarpine‐induced
status epilepticus (SE) model. SE is one of the most com-
mon medical emergencies in patients with epilepsy, and is
clinically defined as a seizure lasting >5 minutes or repeti-
tive seizures within this time frame without regaining con-
sciousness.14 The pilocarpine‐induced SE model is typically
sensitive to most ASDs when they are administered prior to
or commensurate with SE onset; nonetheless, this model is
useful to interrogate pharmacological efficacy in a severe
seizure model. Finally, there is little information on the
potential of CBD to modify epilepsy‐related behavioral
comorbidities despite its preclinical and clinical ability to
provide acute seizure control.6,8–11,13 Furthermore, no pre-
clinical study has yet shown that sustained exposure to
CBD not only reduces seizure burden in a temporal lobe
epilepsy (TLE) model but can also attenuate the severity of
the associated behavioral comorbidities. Therefore, as a
final step we assessed the effects of chronic oral administra-
tion of CBD on spontaneous seizures and associated behav-
ioral comorbidities in the newly developed reduced
intensity SE–induced spontaneous recurrent seizures (RISE‐
SRS) model.15 The RISE‐SRS model exhibits a similar dis-
ease progression and pathology as the traditional post‐SE
rat models, but with reduced mortality during the immediate
post‐SE period. This model provides a platform for the con-
duct of long‐duration disease modification studies with can-
didate investigational therapies. Of note, the present study
utilized a clinically relevant treatment design, as animals
were only enrolled to receive CBD well after the onset of
SRS. The results of the present study indicate that CBD
exerts acute antiseizure efficacy by multiple routes of
administration in several well‐validated preclinical seizure
and epilepsy models with a preclinical profile that is differ-
ent from other prototype ASDs.16,17 Moreover, this present
study provides the first demonstration in a preclinical model
of TLE to suggest that CBD may exert potential disease‐
modifying effects on SRS and attendant behavioral
comorbidities.
Key Points
• CBD is effective in a battery of acute seizure
models following intraperitoneal administration
• CBD is effective in attenuating maximum seizure
severity following intravenous administration in
rats
• Oral CBD can attenuate time-dependent increase
in seizure burden and motor comorbidities in a
rat model of TLE
• Oral CBD can reverse epilepsy-induced cognitive
deficits in a rat model of TLE
• This is the first study to demonstrate the disease-
modifying effect of CBD on spontaneous recur-
rent seizure and associated comorbidities
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2 | MATERIALS AND METHODS
All materials and methods are described in online
Appendix S1.
3 | RESULTS
3.1 | CBD demonstrates acute antiseizure
efficacy following intraperitoneal
administration in a battery of well‐established
acute rodent seizure models
CBD (intraperitoneal [IP]) was initially evaluated for acute
antiseizure efficacy in a battery of well‐defined rodent sei-
zure and epilepsy models (Table 1). These models have
formed the basis for ASD discovery for decades17,18 and
were thus employed to initially define the acute antiseizure
efficacy of CBD relative to standard ASDs.17 For the pur-
poses of the present study, we have also included the effi-
cacy data for the ASDs phenobarbital (PB), valproic acid
(VPA), and felbamate (FBM) as reported in the National
Institute of Neurological Disorders and Stroke public data-
base PANAChE (Table 1). The rotarod test was used to
determine the potential for CBD to induce minimal motor
impairment in mice and to calculate a median behaviorally
impairing dose (TD50). Male mice were found to be
impaired in their ability to perform on the rotorod test at a
TD50 of 272 mg/kg (95% confidence interval [CI] = 241‐
303) when it was administered IP 1 hour prior to testing.
In the antiseizure tests in mice, IP administration of CBD
prior to electrical stimulation was found to block tonic
extension seizures induced by maximal electroshock seizure
(MES) in male mice with a median effective dose (ED50)
of 80.0 mg/kg (95% CI = 65.5‐96.0), yielding a protective
index (PI; TD50/ED50) of 3.4. CBD was also effective in
male mice against clonic seizures induced by subcutaneous
administration of pentylenetetrazol when administered
1 hour prior to testing (ED50 = 120 mg/kg IP, PI = 2.3).
CBD was found to protect male mice against the 6‐Hz par-
tial psychomotor seizure at two different currents following
IP administration. With a 32‐mA stimulation delivered
1 hour after drug administration, CBD had an ED50 of
144 mg/kg, yielding a PI for this test of 1.9. Importantly,
CBD was also found to be effective and retained its
potency at the 44‐mA stimulation current in the 6‐Hz test
when administered 1 hour prior to electrical stimulation;
ED50 at this current and time point of 173 mg/kg (PI =
1.6). Additionally, in male corneal kindled mice, the ED50
of CBD was determined to be 144 mg/kg (PI = 1.9). Thus,
CBD demonstrates broad antiseizure efficacy in several
well‐validated mouse models of acute (MES, subcutaneous
pentylenetetrazol, 6 Hz) and chronic (corneal kindled) sei-
zures at doses well below the motor‐impairing dose.
In male rats, visual evaluation of minimal motor impair-
ment was scored by a trained investigator to determine the
adverse effects of CBD on behavioral performance. Naive
male rats were not found to be impaired on this test follow-
ing administration of CBD doses up to 500 mg/kg; thus, a
TD50 was determined to exceed 500 mg/kg (IP). In the
antiseizure tests in rats, IP administration of CBD 2 hours
prior to electrical stimulation was found to block tonic
extension seizures induced by MES with an ED50 of
53.2 mg/kg, yielding a PI of >9.4. Thus, as demonstrated
in male mice, CBD was effective in the rat MES test at a
dose well below the motor‐impairing dose. Based on this
demonstration of efficacy and tolerability in several well‐
established acute seizure models in rats and mice, CBD
was further evaluated in the pilocarpine‐SE model and an
etiologically relevant rat model of post‐SE TLE.
3.2 | IV administration of CBD reduces
severity of pilocarpine‐induced SE
The pilocarpine‐induced SE model is a well‐established
model of severe generalized seizures that is often used in the
pursuit of novel ASDs. Based on the acute efficacy of CBD
in the rat MES test following IP administration (Table 1),
CBD was administered by the IV route 1 hour prior to the
onset of SE to determine any potential for effect on maximal
SE severity. This dose of CBD was found to significantly
attenuate the maximum seizure severity (MSS; P < 0.05)
compared to the vehicle‐treated group (Figure 1A). To
demonstrate the validity of the protocol and tractability of
the model, we also evaluated the efficacy of a supratherapeu-
tic dose of PB (30 mg/kg IV). Administration of PB 30 min-
utes prior to SE onset significantly reduced the MSS
(P < 0.0001) relative to the vehicle‐treated group (Fig-
ure 1B). It should be emphasized that the doses of CBD ver-
sus PB tested in this model were not pharmacologically
equivalent (Table 1), as the IV dose of CBD was threefold
lower than the rat MES ED50 (IP), whereas the dose of PB
was 15‐fold higher than the rat MES ED50 (IP). Of note, no
mortality was observed in any of the experimental animals
during the behavioral seizure monitoring period. Thus, CBD
pretreatment was found to acutely attenuate MSS in this rat
model of SE to a degree consistent with PB.
3.3 | Chronic oral administration of CBD
attenuates seizure burden in the RISE‐SRS
model of TLE
3.3.1 | Chronic oral administration of CBD
reduces long‐term seizure burden
To evaluate the effect of chronic CBD administration on
disease progression, we examined the effect of treatment
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upon seizure burden and seizure burden ratio of rats dis-
playing chronic epilepsy. The seizure burden ratio was cal-
culated from the seizure burden in each recording session
by using the following formula: seizure burden ratio =
(mean seizure burden in final bin) / (mean seizure burden
in first bin). A higher seizure burden ratio therefore indi-
cates a worsening of the disease over time (Figure 2B and
2C), as is typical of post‐SE rat models of TLE.15,19 The
seizure burden ratio was significantly greater in vehicle‐
treated epileptic animals compared to CBD‐treated epileptic
animals (n = 10 per group; Mann‐Whitney test, U = 22,
P < 0.05; Figure 2B). Moreover, disease severity was
improved (seizure burden ratio < 1) significantly in 70% of
the CBD‐treated animals, in contrast to only 10% of vehi-
cle‐treated rats (Fisher’s exact test, P < 0.05; Figure 2C).
CBD‐treated epileptic rats did not demonstrate a time‐
dependent increase in seizure burden (Wilcoxon matched‐
pairs test, W = −31, P = 0.13; Figure 2E) observed by a
change of median value from 28.50 (interquartile range
[IQR] = 26.81‐39.75) to 24.75 (IQR = 19.69‐35.94),
whereas vehicle‐treated rats showed a robust increase
in seizure burden from a median value of 25.75
TABLE 1 Effect of CBD, PB, VPA, and FBM in acute mouse and rat seizure models
Antiseizure
Test
CBD ED50,
mg/kg
IP (95% CI) PI
CBD
TPE, h
PB ED50, mg/kg
IP (95% CI)a PI
PB
TPE,
h
VPA
ED50 mg/kg
IP (95% CI)a PI
VPA
TPE, h
FBM
ED50 mg/kg
IP (95% CI)a PI
FBM
TPE,
h
Maximal
electroshock,
mouse
80 (65.5‐96.0) 3.4 1 11.3 (9.39‐13.7) 4.0 2 213 (138‐274) 1.8 0.25 49.3 (39.8‐78.3) 9.1 1
Subcutaneous
pentylenetetrazol,
mouse
120 (98.5‐146) 2.3 1 13.9 (12.1‐16.0) 3.3 0.5 305 (212‐403) 1.3 0.25 219 (150‐331) 2.1 1
6 Hz, 32 mA,
mouse
144 (102‐194) 1.9 1 14.8 (8.92‐23.9) 3.1 0.5 139 (92.4‐197) 2.8 0.25 72.9 (55.3‐89.6) 6.2 1
6 Hz, 44 mA,
mouse
173 (136‐213) 1.6 1 No public data available 289 (242‐384) 1.3 0.25 97.5 (79.3‐122) 4.6 1
Corneal kindled
mouse
115 (77.5‐169) 2.4 1 9.42 (7.91‐17.0) 4.8 0.5 174 (135‐208) 2.2 0.25 No public data available
Minimal motor
impairment,
TD50,
mouse rotarod
272 (241‐303) 2 45.5 (41.8‐49.3) 0.25 390 (382‐396) 0.25 452 (363‐563) 1
Maximal
electroshock, rat
53.2 (39.1‐67.0) 9.4 2 2.61 (1.70‐4.04) 15.7 2 212 (167‐256) 2.2 0.25 35.0 (21.9‐52.3) 16.4 0.5
Minimal motor
impairment,
TD50,
rat open field
analysis
> 500 (ND) ND 41.2 (37.0‐46.6) 0.5 470 (431‐497) 0.5 573 (285‐886) 1
Maximal
electroshock,
formulation
vehicle, mice
0/4 protected 1 Methylcellulose; no public
data available
Methylcellulose; no public
data available
Methylcellulose; no public
data available
6 Hz, 32 mA,
formulation
vehicle, mice
0/4 protected 1 Methylcellulose; no public
data available
Methylcellulose; no public
data available
Methylcellulose; no public
data available
Maximal
electroshock,
formulation
vehicle, rats
0/4 protected 1 Methylcellulose; no public
data available
Methylcellulose; no public
data available
Methylcellulose; no public
data available
CBD, cannabidiol; CI, confidence interval; ED50, median effective dose; FBM, felbamate; IP, intraperitoneal; ND, not done; PB, phenobarbital; PI, protective index;
TD50, median behaviorally impairing dose; TPE, time to peak effect; VPA, valproic acid.
aData are from the National Institute of Neurological Disorders and Stroke PANAChE database (https://panache.ninds.nih.gov/ChemDetail.aspx?CHEM_ID=
2&TEST_NO=7B#seereport).
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(IQR = 18.94‐39.34) to 30.13 (IQR = 21.00‐49.91) in this
same time period (Wilcoxon matched‐pairs test, W = 53,
P < 0.01; Figure 2D).
3.3.2 | Chronic oral administration of CBD
to RISE‐SRS rats attenuates the severity of
behavioral comorbidities of TLE
Motor coordination
Motor coordination was tested with the accelerating rotarod
test. A significant difference in time spent on the accelerat-
ing rod was observed among the groups (one‐way analysis
of variance [ANOVA], F2, 27 = 5.996, P < 0.01). The
Holm‐Sidak post hoc test revealed that naive vehicle‐trea-
ted (P < 0.05) and epileptic CBD‐treated (P < 0.01) ani-
mals spent significantly more time on the rod, compared to
the epileptic vehicle‐treated group. This motor test indicates
that chronic oral CBD administration attenuated the TLE‐
induced motor dysfunction (Figure 3A).
Gait
The gait test was performed to assess left stride length,
right stride length, and stride width of the animals. No sig-
nificant differences among the groups were observed for
any of these parameters (one‐way ANOVA; for left stride
length, F2, 27 = 0.019; for right stride length, F2,
27 = 0.198; for stride width, F2, 27 = 0.842; Figure 3B‐D).
Furthermore, as animals were actively on CBD or vehicle
therapy during this motor performance test, this study
demonstrates that the dose of CBD necessary to reduce sei-
zure burden was not associated with motor‐impairing
effects in rats with SRS.
Cognitive function
To assess the effect of CBD on cognitive performance,
epileptic animals were challenged in the hole board test of
reference and working memory. In this study, an age‐
matched cohort of nonepileptic, naive rats was also included
to determine whether chronic CBD administration could
normalize behavioral performance. Chronic oral administra-
tion of CBD to epileptic rats was found to significantly
reduce the number of reference memory errors (RMEs) and
working memory errors (Figure 4). A significant difference
in RMEs was observed among the groups (one‐way
ANOVA, F2, 42 = 15.06, P < 0.0001). Here, the naive
vehicle‐treated (P < 0.0001) and epileptic CBD‐treated
(P < 0.05) rats made significantly fewer RMEs (Figure 4A)
compared to the epileptic vehicle‐treated rats (Holm‐Sidak
post hoc test). However, the CBD‐treated epileptic rats
made significantly more RMEs when compared to the naive
vehicle‐treated group (Holm‐Sidak post hoc test, P < 0.05).
Therefore, CBD failed to completely restore the reference
memory in epileptic animals to the extent of their naive,
nonepileptic controls. Working memory was similarly
affected (one‐way ANOVA, F2, 42 = 35.72, P < 0.0001;
Figure 4B), with the epileptic vehicle‐treated group
FIGURE 1 Acute administration of subtherapeutic doses of cannabidiol (CBD) attenuates maximum seizure severity to a similar degree as
supratherapeutic doses of the prototype antiseizure drug, phenobarbital (PB), in the pilocarpine‐induced status epilepticus rat model. A, Median
maximum seizure severity of vehicle (n = 15) and CBD (n = 12, 10 mg/kg intravenous [IV]). CBD or vehicle was administered to rats 1 hour
prior to systemic administration of the chemoconvulsant pilocarpine. CBD‐treated rats demonstrated significantly reduced maximum seizure
severity compared to vehicle‐treated rats. B, Median maximum seizure severity of PB (n = 13, 30 mg/kg IV) and its vehicle (n = 12). PB or
vehicle was administered to rats 1 hour prior to systemic administration of the chemoconvulsant pilocarpine. PB‐treated rats demonstrated
significantly reduced maximum seizure severity compared to vehicle‐treated rats (raw maximum seizure severity data), confirming the therapeutic
responsiveness of the model. Data are expressed as median, minimum to maximum, and interquartile range. Data were analyzed by Mann‐
Whitney test, *P < 0.05, ****P < 0.0001
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FIGURE 2 Chronic administration of cannabidiol (CBD) modifies the overall spontaneous seizure burden ratio and seizure burden in the
reduced intensity status epilepticus (SE)–induced spontaneous recurrent seizures (SRS) rat model of chronic temporal lobe epilepsy up to 7 weeks
postinsult. A, Study time line for the epileptic animals. PSBB, postseizure behavioral battery. B, Median seizure burden ratio of epileptic vehicle‐
treated and epileptic CBD‐treated animals recorded during a 7‐week continuous video monitoring period. CBD significantly reduced the seizure
burden ratio compared to the vehicle‐treated counterpart (n = 10/group; data were analyzed by Mann‐Whitney test, *P < 0.05). Data are
expressed as median, minimum to maximum, and interquartile range. C, Number of epileptic vehicle‐treated and epileptic CBD‐treated animals
with seizure burden ratio < or > 1 (data were analyzed by Fisher’s exact test, *P < 0.05). D, Median seizure burden before and after vehicle
treatment. Seizure burden was increased significantly in this group at the end of the observation period (n = 10; data were analyzed by Wilcoxon
matched‐pairs signed‐rank test, **P < 0.01). E, Median seizure burden before and after CBD treatment. CBD‐treated rats showed no change in
seizure burden (n = 10; data were analyzed by Wilcoxon matched‐pairs signed‐rank test)
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FIGURE 3 Chronic administration of cannabidiol (CBD) to spontaneously epileptic rats improves some indices of motor coordination 6
weeks after status epilepticus. A, Mean time (in seconds) spent on accelerated rotarod. The naive vehicle‐treated and epileptic CBD‐treated
groups spent significantly more time on the accelerating rotarod compared to the epileptic vehicle‐treated group (n = 10/group). B, There were
no significant differences in mean left stride length (in millimeters) of naive vehicle‐treated, epileptic vehicle‐treated, and epileptic CBD‐treated
rats (n = 10/group). C, There were no significant differences in mean right stride length (in millimeters) between naive vehicle‐treated, epileptic
vehicle‐treated, and epileptic CBD‐treated rats (n = 10/group). D, There were no significant differences in mean stride width (in millimeters) of
naive vehicle‐treated, epileptic vehicle‐treated, and epileptic CBD‐treated rats (n = 10/group). Data are expressed as mean ± SEM. Data were
analyzed by one‐way analysis of variance with Holm‐Sidak post hoc test, *P < 0.05, **P < 0.01
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demonstrating significantly more errors compared to the
naive vehicle‐treated group (Holm‐Sidak post hoc test,
P < 0.0001). Importantly, chronic CBD‐treated rats demon-
strated significantly fewer working memory errors com-
pared to epileptic vehicle‐treated animals (Holm‐Sidak post
hoc test, P < 0.0001). Interestingly, working memory per-
formance for CBD‐treated epileptic rats was superior to the
naive vehicle‐treated group (Holm‐Sidak post hoc test,
P < 0.05).
4 | DISCUSSION
In the present study, we have demonstrated the acute anti-
seizure efficacy of CBD in a battery of well‐defined and estab-
lished acute seizure tests in both mice and rats following IP
administration. Our findings are consistent with other reports
of the acute antiseizure efficacy of CBD in numerous preclini-
cal seizure models.10,20 We have also demonstrated that acute
IV administration of a subtherapeutic dose of CBD is able to
significantly attenuate the MSS in the rat pilocarpine‐induced
SE model to a similar degree as a supratherapeutic dose of the
prototype ASD, PB. Furthermore, we have demonstrated for
the first time that chronic oral administration of CBD
improves seizure burden ratio, motor comorbidities, and cog-
nitive function in the RISE‐SRS model of TLE in rats well
after the onset of symptomatic seizures. Altogether, the pre-
sent study further supports a growing body of evidence to
demonstrate that CBD is a well‐tolerated and effective therapy
for acute and chronic seizures,11 as well as now demonstrating
the potential that chronic oral administration of CBD may
confer disease‐modifying effects in an etiologically relevant
preclinical model of TLE.
All of the FDA‐approved ASDs exhibit acute anti-
seizure efficacy in one or more of the acute seizure and
epilepsy models presently used for the evaluation of
CBD.16,21 However, many of the FDA‐approved ASDs are
associated with significant motor adverse effects that may
limit clinical utility. In this regard, we presently provide
pharmacological data that suggest differentiation between
CBD and the FDA‐approved ASD, PB (Table 1). Of note,
the activity profile of CBD in these acute seizure models is
generally comparable to PB (Table 1). CBD is thus differ-
entiated from numerous ASDs with broad‐spectrum effi-
cacy, including another broad‐spectrum ASD, VPA
(Table 1), because of this wide margin separating anti-
seizure efficacy and minimal motor impairment in numer-
ous preclinical seizure models. The broad‐spectrum
efficacy and margin of safety of CBD are more directly
comparable to FBM (Table 1), which, like CBD, is also
approved for patients with Lennox‐Gastaut syndrome.22
CBD presently demonstrated efficacy in the acute mouse
MES, subcutaneous pentylenetetrazol, and 6‐Hz assays at
both 32‐ and 44‐mA stimulus intensities. CBD also demon-
strated a PI > 1.5 in the 6‐Hz model of pharmacoresistant
epilepsy at a 44‐mA stimulus intensity, which substantially
differentiates this compound from many other FDA‐
approved ASDs, including VPA.23,24 The activity of FBM
is also preserved in the 44‐mA version of the 6‐Hz assay
(Table 1); the PI of FBM is also much greater than CBD
FIGURE 4 Chronic administration of cannabidiol (CBD) to reduced intensity status epilepticus–induced spontaneous recurrent seizures rats
reduces onset of behavioral comorbidities of epilepsy in the hole‐board task of spatial memory. A, Mean reference memory errors in naive
vehicle‐treated, epileptic vehicle‐treated, and epileptic CBD‐treated groups (n = 15 mean trial/group). CBD significantly improved reference
memory error compared to the vehicle‐treated epileptic group. B, Mean working memory errors. CBD significantly improved working memory
error compared to the naive vehicle‐treated and epileptic vehicle‐treated groups. Data are expressed as mean ± SEM. Data were analyzed by one‐
way analysis of variance with Holm‐Sidak multiple comparison test, *P < 0.05, ****P < 0.0001
310 | PATRA ET AL.
in this assay (4.6 for FBM vs 1.6 for CBD; Table 1). As
the 6‐Hz stimulation intensity increases from 32 to 44 mA,
most ASDs lose efficacy or are only effective at motor‐
impairing doses16,17,23,25; thus, the finding that CBD
retained efficacy and potency at both stimulation intensities
in this assay at doses well below the mouse TD50
(272 mg/kg IP) suggests that CBD is highly differentiated
from other FDA‐approved ASDs (eg, PB and VPA;
Table 1) and suggests potential for efficacy in pharmacore-
sistant patient populations akin to FBM. Unlike FBM, there
have been no reports to date of hepatotoxicity or aplastic
anemia with CBD use,26,27 but whether other clinical
adverse events will emerge with greater clinical use of this
agent remains to be determined.
The presently reported ED50 values in these acute mouse
assays align with work reported by Klein and colleagues
using CBD provided by the US National Institute of Drug
Abuse10 and by an independent laboratory using the same
CF‐1 mouse strain.28 However, we presently report signifi-
cantly greater potency of CBD in the rat MES test than that
reported by Klein and colleagues (ED50 = 88.9 mg/kg [95%
CI = 69‐124] IP10), likely due to differences in compound
formulation, source, and purity. We also report that CBD
exerted dose‐dependent reductions in seizure score in the
corneal kindled mouse model of chronic focal seizures, fur-
ther suggesting that CBD is effective as an antiseizure agent
in an epileptic substrate (ie, kindled rodents). Altogether, the
presently reported pharmacological profile of CBD supports
further evaluation of its broad clinical utility for epilepsy.
IV administration of CBD also reduced MSS in the
pilocarpine‐induced SE in rats (Figure 1A), consistent with
earlier findings demonstrating efficacy of a preclinical
CBD formulation administered via the IP route.9 We
believe this is the first demonstration of the efficacy of IV
CBD against the onset of SE, with this route of administra-
tion most commonly employed in the treatment of clinical
SE.6,9 Although further studies are needed to define
whether IV CBD can effectively reduce MSS after the
onset of SE (eg, against benzodiazepine‐resistant SE), the
present results in the pilocarpine‐SE model further support
the acute antiseizure efficacy of CBD in diverse preclinical
models of seizure.
TLE is one of the most common forms of acquired epi-
lepsy in humans.29 Therefore, we investigated the effect of
a clinically relevant CBD administration protocol in the
RISE‐SRS model of TLE.15 We presently demonstrate that
CBD is disease‐modifying in this model, where all animals
exhibit SRS before being assigned to treatment groups.
Specifically, chronic oral administration of CBD signifi-
cantly decreased the seizure burden ratio of epileptic ani-
mals and improved reference memory function. Although
CBD did not significantly reduce seizure burden after
7 weeks of treatment, it did markedly modify the natural
disease course following SE, as demonstrated by no overall
increase in the seizure burden from the first to final seizure
monitoring bin (Figure 2). These findings are in stark con-
trast to the vehicle‐treated post‐SE rats, which demon-
strated a notable, time‐dependent increase in disease
severity (ie, seizure burden ratio increased). Disease sever-
ity, as characterized by a seizure burden ratio < 1, was
improved in 70% of the CBD‐treated animals, in contrast
to only 10% of vehicle‐treated rats attaining such a ratio
(Figure 2). Although several FDA‐approved ASDs have
demonstrated disease‐modifying potential in preclinical
models of chronic seizure,30,31 and CBD has been found to
be disease‐modifying in a mouse model of Dravet syn-
drome,32 to our knowledge, this is the first study to demon-
strate such an effect with CBD in any preclinical TLE
model. The third‐generation ASD topiramate has demon-
strated some potential for cognitive sparing and modifica-
tion of behavioral deficits when administered shortly after
SE onset,33,34 but no study has yet demonstrated such a
disease‐modifying effect when treatment is initiated well
after the SE insult (8 weeks in present study). Although
our study did not include a CBD washout arm, the present
results demonstrate that chronic oral administration of CBD
is associated with long‐term improvements in disease tra-
jectory in this rat model of epilepsy.
A number of ASDs (eg, PB, VPA, phenytoin) are
reported to have an adverse effect on motor function char-
acterized by dyskinesia in people with epilepsy.5,35–37
Moreover, patients on phenytoin and VPA treatment some-
times exhibit parkinsonism.5 Although we presently
demonstrate that acute administration of CBD is well toler-
ated at doses up to 500 mg/kg (IP) in naive rats (Table 1),
in line with prior reports,9 no studies have yet been con-
ducted to examine the long‐term effects of chronic CBD
administration on tolerability and motor function in epilep-
tic animals. Furthermore, no study has yet administered
CBD for disease modification purposes after the onset of
SRS. In this regard, the present study employed a clinically
realistic treatment scenario in a preclinical model of TLE
to demonstrate that chronic oral administration of CBD is
associated with notable antiseizure efficacy, minimal
adverse effects liability, and disease‐modifying potential
well after the onset of symptomatic seizures.
It is well known that humans and animals with epilepsy
are more sensitive to adverse effects of ASDs38; thus, our
present findings that chronic oral administration of CBD in
rats with epilepsy was not associated with any adverse
effects further supports the potential of this agent for chronic
clinical use in epilepsy patient populations. In addition to
these drug‐induced adverse effects on motor function, motor
deficits are one of the most common comorbidities exhibited
by patients with epilepsy.39 Here, we used two well‐vali-
dated models of motor function to assess the fine motor
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control, balance, and gait of animals. Epileptic vehicle‐trea-
ted animals fell from the accelerating rotarod sooner than the
naive vehicle‐treated ones, indicating that SRS produced sig-
nificant motor dysfunction related to balance. Similar find-
ings were reported previously in the rotarod40 test, where
motor dysfunction was exhibited by epileptic rats. In con-
trast, CBD‐treated animals remained on the accelerating
rotarod for a significantly longer time than the vehicle‐trea-
ted epileptic animals. Thus, we show for the first time that
CBD is not only well‐tolerated by epileptic animals after pro-
longed oral administration, but that CBD reduces the severity
of motor deficits induced by epilepsy.
Epileptic rats performed comparably to healthy animals
in the gait test, which is consistent with gait disorders being
rarely reported in adult epileptic patients with TLE. How-
ever, ASDs such as VPA and lacosamide have a detrimental
effect on gait in human patients.35,37 It should be emphasized
that animals were in the active CBD administration period
during this motor test, suggesting that CBD at the dose tested
did not confer any adverse effects on motor coordination.
Our results demonstrate that chronic oral administration of
CBD did not have any adverse effect on gait in rats with epi-
lepsy. Clinical trials conducted on Dravet syndrome and
Lennox‐Gastaut syndrome patients also did not report any
gait disturbances following CBD administration.11,13
Whether these side effects may also be absent in the general
TLE patient population remains to be further determined.
Cognitive decline is a common comorbidity associated
with TLE.41 For example, patients with TLE often exhibit
poor executive control and working memory deficits,42 and
amnesia or accelerated long‐term loss of memory is also fre-
quently reported in patients with TLE.43 Cognitive function
in animals is typically assessed using spatial memory tasks
measuring reference memory and working memory
errors.32,33 Reference memory can be defined as long‐term
storage of acquired information that remains constant over
successive training sessions, whereas working memory is a
form of short‐term memory that refers to storage and
manipulation of information acquired within a trial ses-
sion.44 Several spatial memory tasks (eg, radial arm maze,
Morris water maze, hole‐board task) have been used to
evaluate these two types of memory in rodents.45,46 Here,
we employed the hole‐board task, where epileptic vehicle‐
treated rats exhibited impairment of both the working and
reference memory aspects of the hole‐board test. These
findings are comparable with previous studies of spatial or
hippocampus‐dependent memory in rats with TLE, for
example, a delayed nonmatching to position task,47 eight
arm radial maze,48 and Morris water maze.49 In contrast,
CBD‐treated epileptic animals exhibited improved reference
memory function compared to epileptic vehicle‐treated ani-
mals; however, reference memory function was not restored
to levels seen in healthy animals. Interestingly, our study
shows that chronic oral administration of CBD improved
working memory function compared to both epileptic vehi-
cle‐treated and naive vehicle‐treated animals. However, as
we did not include a nonepileptic CBD treated group in our
design, we are unable to ascertain whether CBD has mem-
ory enhancement properties in healthy animals. A memory‐
enhancement effect would be unusual, as previous studies
using a radial arm maze have shown that CBD does not
improve working memory function in healthy mice.50,51
Given that the integrity of the blood‐brain barrier is com-
monly disrupted in epilepsy,52 a limitation of the present
study is that we did not determine whether higher CBD
concentrations were present in the brains of these epileptic
rats. Thus, the dose of CBD required to reach this concen-
tration might not be therapeutically significant in healthy
animals. Although SRS are the primary cause of cognitive
decline in TLE,53 the improved cognitive function in the
CBD‐treated epileptic group might be due to a seizure‐inde-
pendent mechanism rather than solely by seizure reduction,
for example, anti‐inflammatory/neuroprotective action.6
However, further detailed investigation is thus warranted to
shed light on the mechanism by which CBD improved the
presently tested behavioral comorbidities.
Epidiolex (CBD) was approved by the FDA in 2018 for
the treatment of seizures in the catastrophic pediatric ence-
phalopathies Dravet syndrome and Lennox‐Gastaut syn-
drome. The present study has demonstrated that CBD is
also a good potential candidate drug for the treatment of
spontaneous symptomatic seizures of TLE. Moreover,
chronic oral administration of CBD also reduced severity
of motor disorders and cognitive deficits typically associ-
ated with TLE, in line with prior demonstrations of dis-
ease‐modifying effects in a mouse model of Dravet
syndrome.32 Taken altogether, this study further illustrates
that CBD not only is a potent and broad‐spectrum ASD,
but may also find use to attenuate cognitive deficits associ-
ated with TLE well after the onset of SRS.41 More detailed
studies are thus required to investigate the potential mecha-
nism of action for CBD as a disease‐modifying agent for
the patient with epilepsy.
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